Patents Examined by Regina M. DeBerry
  • Patent number: 11981718
    Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: May 14, 2024
    Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.
    Inventors: Zhao Dong, Chi Zhou, Xiong Feng, Jiyu Zhang, Shixiang Jia, Qiang Li
  • Patent number: 11969459
    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 30, 2024
    Assignees: StemRIM Inc., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Yoshiki Sawa, Shigeru Miyagawa, Takashi Kido, Takasumi Goto, Takehiko Yamazaki
  • Patent number: 11945872
    Abstract: The present invention provides monoclonal antibodies that bind to the Activin A type I receptor (ACVR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to ACVR1. In some embodiments, the antibodies of the invention are useful for inhibiting ACVR1-mediated bone morphogenetic protein (BMP) signal transduction, thus providing a means of treating or preventing a disease, disorder or condition associated with ACVR1.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: April 2, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Vincent J. Idone, Sarah J. Hatsell, Aris N. Economides
  • Patent number: 11931325
    Abstract: Novel compositions that promote hair growth or hair restoration, and compositions that prevent hair loss. Compositions including an iNOS inhibitor as an active ingredient are provided. Advantageous affects for hair growth or hair restoration are obtained when a composition including an iNOS inhibitor as an active ingredient is administered to a mammal. For the iNOS inhibitor, a low-molecular compound, an antibody, or a nucleic acid drug such as an antisense oligonucleotide or siRNA may be used. A method of screening for effective substances for promotion of hair growth or hair restoration or prevention of hair loss is also provided.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: March 19, 2024
    Assignee: EADERM CO., LTD.
    Inventors: Shohei Shinozaki, Kentaro Shimokado
  • Patent number: 11891423
    Abstract: Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10?8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRP? without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: February 6, 2024
    Assignees: HANGZHOU SUMGEN BIOTECH CO., LTD., SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
    Inventors: Ming Lv, Xiaoran Ding, Shiwei Miao, Bin Tan, Xuegong Wang
  • Patent number: 11890354
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 6, 2024
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 11891447
    Abstract: Methods for treating cancer and/or reducing sternness of cancer stem cells in a subject using a CD14 antagonist, which may be an anti-CD14 antibody.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 6, 2024
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventor: Huei-Wen Chen
  • Patent number: 11884719
    Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 30, 2024
    Assignee: 23andMe, Inc.
    Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
  • Patent number: 11826401
    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 28, 2023
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Yoshiki Sawa, Shigeru Miyagawa, Takashi Kido, Takasumi Goto, Takehiko Yamazaki
  • Patent number: 11773149
    Abstract: This invention provides an NBP158 recombinant protein, a recombinant or synthetic NBP158 mutant protein, a pharmaceutical compositions comprising the NBP158 recombinant protein, and a method for treating metabolic disorders and conditions using such a pharmaceutical composition.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: October 3, 2023
    Inventor: Wentao Zhang
  • Patent number: 11767520
    Abstract: Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 26, 2023
    Assignee: aTyr Pharma, Inc.
    Inventors: John D. Mendlein, Kathleen Ogilvie
  • Patent number: 11739142
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 29, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jens Fischer, Guy Georges, Anton Jochner, Gregor Jordan, Hubert Kettenberger, Joerg Moelleken, Tilman Schlothauer, Georg Tiefenthaler, Valeria Runza, Meher Majety, Martin Schaefer, Maria Viert, Shu Feng, Wei Shiong Adrian Ho, Siok Wan Gan, Runyi Adeline Lam, Michael Gertz
  • Patent number: 11723957
    Abstract: The present invention provides methods for treating a stiffened joint in a subject that comprise administering relaxin, e.g., a PEGylated relaxin-2, to the subject. The relaxin may be administered intra-articularly as a sustained release formulation. The present invention also provides sustained release formulations in the form of a hydrogel for administering polypeptides that are covalently attached to a polymer, e.g., PEG.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: August 15, 2023
    Assignees: Beth Israel Deaconess Medical Center, Inc., Trustees of Boston University
    Inventors: Ara Nazarian, Edward Rodriguez, Mark Grinstaff
  • Patent number: 11680101
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 20, 2023
    Assignee: KYMAB LIMITED
    Inventors: Joana De Abreu Carvalho, Steve Holmes, Allan Lawrie
  • Patent number: 11667704
    Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 6, 2023
    Assignees: BEIJING BEYOND BIOTECHNOLOGY CO., LTD, HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Pinliang Hu, Jing Zou, Weidong Hong, Yun He, Jie Bai, Lingyun Song, Wendi Yang, Zhijian Lv, Shaoyun Xiang
  • Patent number: 11648308
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 16, 2023
    Assignee: Kymab Limited
    Inventors: Volker Germaschewski, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
  • Patent number: 11650209
    Abstract: The present disclosure relates to a polypeptide including an Fc-gamma receptor mutant. The Fc-gamma receptor mutant of the present disclosure is optimized by substituting a part of an amino acid sequence of an Fc-gamma receptor with a different amino acid sequence, so as to provide an excellent selective binding ability to immunoglobulins. Therefore, it can be usefully used for increasing in vivo half-life of drugs, detecting and purifying immunoglobulins, inhibiting organ transplant rejections, or preventing or treating autoimmune diseases.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: May 16, 2023
    Assignee: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
    Inventors: Sang Taek Jung, Migyeong Jo, Sanghwan Ko, Bora Hwang
  • Patent number: 11608381
    Abstract: Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: March 21, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jesper Gromada, Panayiotis Stevis, Judith Altarejos, Andrew J. Murphy
  • Patent number: 11564973
    Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: January 31, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EVIVE BIOTECHNOLOGY (SHANGHAI) LTD
    Inventors: Marcel Van Den Brink, Alan Hanash, Caroline Lindemans, Tom Tang
  • Patent number: 11560416
    Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: January 24, 2023
    Assignee: YUHAN CORPORATION
    Inventors: Byung Hyun Choi, In Hwan Lim, Jun Young Park, Jin Hyoung Lee, Ki Hong Kim, Hae Yong Jo, Jun Hwan Kim, Moo Young Song, Jong Gyun Kim